There has been a resurgence in the debate about the clinical use of Psychedelic therapies or psychedelic-assisted psychotherapy (PAP). There’s been increased legalization of substances and ketamine has been the most-studied psychedelic drug for its promising response to treating mental health conditions especially when it comes to healing patients from past trauma. Journey Clinical is a prescription service that allows Psychotherapists to prescribe ketamine-assisted psychotherapy to unlock a new care pathway for patients for whom traditional pharmacological routes have not worked. Psychedelics are said to increase suggestibility, making patients more open to concepts brought up in therapy as well as resulting in neurotransmitter changes causing an improvement in mood. AlleyWatch caught up with Journey Clinic CEO Jonathan Sabbagh to learn more about the company’s mission to make psychedelic therapy more accessible and mainstream, how his personal journey overworked in finance led the AHA moment, strategic plans, latest round of funding from investors that include Fifty Years Neo Kuma Ventures, Palo Santo, PsyMed Ventures, and Lionheart Ventures.